Quartalszahlen Thermogenesis - 500 Beiträge pro Seite

[RudiDutschke]

Guten Tag,
die für letzten Donnerstag angekündigten Zahlen sind da.
Nachzulesen unter www.freerealtime.com
Auf der Homepage noch nicht zu finden.
Grüsse

[CaptainChaos]

THERMOGENESIS CORP. Announces 32% Increase in Revenues for the Quarter Ended December 31, 2000; ``Company Posts A 14% Improvement in Gross Profit Margin``
RANCHO CORDOVA, Calif.--(BUSINESS WIRE)--Feb. 9, 2001-- THERMOGENESIS CORP. (Nasdaq:KOOL) today announced results for its second quarter of fiscal 2001. The Company reported net revenues of 1,729,000 and 2,530,000 for the three and six months ended December 31, 2000, a 32 and 9 improvement over the comparable periods in the prior year. Gross profit as a percentage of net revenues increased to 18 from 4 and to 7 from (9) for the three and six months ended December 31, 2000, respectively.

Revenues increased due to greater sales of BioArchive and ThermoLine products. The number of BioArchive units sold doubled in the first six months of this fiscal year compared to last year. ThermoLine revenues increased 44 and 10 for the three and six months ended December 31, 2000, primarily due to a restructured sales department to include an experienced field-based sales executive to call on domestic customers. Ten MP2000 freezers, eight to Aventis Bio-Services, Inc., were sold in the three and six months ended December 31, 2000 versus one and five in the comparable periods in the prior year.

Commenting on the results, James H. Godsey, President and C.O.O., stated "Posting revenues of 1,729,000 represents our highest quarter since the initial launching of the BioArchive product line in FY1998. The increase in revenues is a direct result of the enhanced sales effort to BioArchive customers as well as Aventis` continued commitment to ThermoGenesis` ultra rapid freezing technology."

The improvement in the gross margin as a percentage of revenues was achieved through lower manufacturing overhead as a result of better inventory management and cost control measures implemented by the Company last year, as well as increased sales of products with higher margins, such as the MP2000 freezers.

General and Administrative expenses for the quarter ended December 31, 2000 decreased 3 from the corresponding fiscal 2000 period due to personnel reductions which occurred during the prior fiscal year and the Company has elected not to replace the vacant positions. Selling and Service expenses decreased 5 from the corresponding fiscal 2000 period as a result of cost control measures focused on reduction of travel related expenses and reduction in the use of outside consultants. Research and Development expenses increased 4 due to adding more resources in the Company`s regulatory department and other expenses associated with the CryoSeal Fibrin Sealant pre-clinical trials.

Dr. Godsey, commenting on the overall performance, noted, "With the increase in revenues, we are beginning to see the improvement in gross margin and operating results we have been working towards. We anticipate additional improvements in our financial results as the stem cell market begins to expand and the CryoSeal Fibrin Sealant product is launched in each major geographical area."

The Company will hold an analyst and market conference call to review and discuss the results of operations on Monday, February 12, 2001 at 1:00 PST. Interested investors can listen to the conference call by dialing [phone]. Additionally, a taped playback of the conference call will be available from February 12, 2001 6:00 pm EST through February 20, 2001 12:00 am EST. Access to the tape playback is available by dialing [phone] Account : 614 (pound sign) Conference: 224255 (pound sign). If you have any questions or experience problems accessing the taped playback, please contact Nitza Mihalus at [phone] during the Company`s normal business hours. The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the Company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.

For More Information Contact:
Investor Relations
THERMOGENESIS CORP.
Renee M. Ruecker, V.P. Finance: [e-mail]
(916) 8585100 THERMOGENESIS CORP.
Condensed Statements of Operations
(Unaudited) Three Months Ended Six Months Ended
December 31, December 31,
2000 1999 2000 1999Net revenues $1,729,000 $1,313,000 $2,530,000 $2,311,000
Cost of revenues 1,425,000 1,266,000 2,351,000 2,518,000 Gross profit 304,000 47,000 179,000 (207,000)Expenses:
General and
administrative 440,000 454,000 855,000 917,000
Selling and service 533,000 560,000 1,011,000 1,131,000
Research
and development 435,000 419,000 870,000 895,000 Total expenses 1,408,000 1,433,000 2,736,000 2,943,000Other income/expenses (6,000) 6,000 24,000 16,000Net loss before
preferred stock
dividend or discount
and cumulative effect
of accounting change ($1,110,000)($1,380,000)($2,533,000)($3,134,000)Preferred stock
dividend or discount 23,000 313,000 73,000 313,000
Cumulative effect
of accounting change 580,000 580,000 Net loss to
common stockholders ($1,713,000)($1,693,000)($3,186,000)($3,447,000) THERMOGENESIS CORP.
Condensed Balance Sheets
(Unaudited) December 31, June 30,
2000 2000
ASSETS
Current assets:
Cash, cash equivalents
and short term investments $2,555,000 $2,550,000
Accounts receivable, net 1,056,000 627,000
Inventory 2,080,000 2,275,000
Other current assets 154,000 150,000 Total current assets 5,845,000 5,602,000Equipment, net 947,000 1,080,000Other assets 52,000 53,000 $6,844,000 $6,735,000LIABILITIES AND SHAREHOLDERS` EQUITYCurrent liabilities:
Accounts payable $696,000 $512,000
Shortterm debt 1,634,000
Other current liabilities 541,000 477,000 Total current liabilities 2,871,000 989,000Longterm portion of
capital lease obligations 54,000 54,000Shareholders` equity 3,919,000 5,692,000 $6,844,000 $6,735,000